COVID-19 and Rates of Cancer Diagnosis in the US
This population-based cross-sectional study of US cancer incidence trends found that rates of diagnosis improved in 2021 but continued to be lower than expected, adding to the existing deficit of diagnosed cases from 2020. Particular attention should be directed at strategies to immediately increase cancer screenings to make up lost ground.
Authors
- Feitong Lei (ORCID: https://orcid.org/0000-0002-1757-4858)
- Svetla Slavova
- W. Jay Christian (ORCID: https://orcid.org/0000-0001-6904-3971)
- Amanda R. Ellis (ORCID: https://orcid.org/0000-0002-5835-3285)
- Todd Burus (ORCID: https://orcid.org/0000-0001-6819-1788)
- Bin Huang (ORCID: https://orcid.org/0000-0002-9075-1531)
- Pamela C. Hull (ORCID: https://orcid.org/0000-0003-4412-9087)
- Krystle A. Lang Kuhs (ORCID: https://orcid.org/0000-0002-7643-9330)
- T. C. Tucker (ORCID: https://orcid.org/0000-0002-5993-484X)
Institutions
- University of Kentucky (US)
- Markey Cancer Center (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.32288
- Citations
- 30
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 8.48
Funders
- Eli Lilly and Company
- St. Jude Children's Research Hospital
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute